{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03367299\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["blinatumomab","chemotherapy"]],"indication":"adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","name":"GIMEMA LAL2317","nct_id":"NCT03367299","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=gimema-lal2317-nct03367299. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LAL2317","arms":[{"description":"Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.","label":"Chemotherapy + Blinatumomab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-09-02","type":"ACTUAL"},"conditions":["Acute Lymphoid Leukemia","Philadelphia Chromosome-Negative B-Cell Precursor"],"enrollment":{"count":149,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Chemotherapy + Blinatumomab","otherNames":[],"type":"DRUG"}],"last_update":"2025-01-22","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","official_title":"National Treatment Program With Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-09-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of patients that obtain a negative Minimal Residual Disease (MRD)","timeFrame":"At week 14 from study entry"}],"references":[{"citation":"Bassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M, Elia L, Cardinali D, De Propris MS, Piccini M, Lussana F, Annunziata M, Chiusolo P, Zappasodi P, Borlenghi E, Leoncin M, Califano C, Bocchia M, Di Raimondo F, Grimaldi F, Tiribelli M, Candoni A, Lico A, Audisio E, Lunghi M, Mianulli AM, Di Trani M, Arena V, Messina M, Piciocchi A, Fazi P, Rambaldi A, Foa R. Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025 May 22;145(21):2447-2459. doi: 10.1182/blood.2024027500.","pmid":"40009490","type":"DERIVED"}],"start_date":{"date":"2018-06-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia","url":"https://clinicaltrials.gov/study/NCT03367299"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/gimema-lal2317-nct03367299"}